Test Price
2,800 AED✅ Home Collection Available
UMOD Gene Hyperuricemic Nephropathy, Familial Juvenile Type 1 Genetic Test in UAE – 2800 AED – Precision Diagnostics for Hereditary Kidney Disease
Executive Summary & Core Metrics
Core Metrics – UMOD Gene NGS Analysis at DNA Labs UAE
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Certified Next-Generation Sequencing on Illumina NovaSeq X Plus platform.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post‑Test Clinical Interpretation by Consultant Medical Genetics included in every report.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This test employs Next‑Generation Sequencing (NGS) to detect pathogenic and likely‑pathogenic variants in the UMOD gene, which encodes uromodulin (Tamm–Horsfall protein). Mutations in UMOD cause familial juvenile hyperuricemic nephropathy type 1 (FJHN1), a rare autosomal dominant tubulointerstitial kidney disease characterised by early‑onset gout, progressive renal impairment, and hyperuricemia disproportionate to the degree of kidney dysfunction. Early molecular diagnosis enables targeted urate‑lowering therapy, cascade screening in at‑risk relatives, and informed family planning.
| Feature | Our UMOD NGS Test (AED 2,800) | Traditional Sanger Sequencing |
|---|---|---|
| Methodology | Next‑Generation Sequencing (Illumina NovaSeq X Plus, paired‑end 150 bp) | Sanger Sequencing (capillary electrophoresis) |
| Turnaround Time | 21–28 calendar days (clinically validated reporting) | 35–42 calendar days |
| Gene Coverage | Full gene ±20 kb flanking regions, deep intronic and promoter variants | Exons only (non‑coding pathogenic variants missed) |
| Analytical Sensitivity | >99.9% for single‑nucleotide variants and indels; validated CNV detection | ~95% – limited by exon capture and read depth |
| UAE Regulatory Alignment | DHA‑licensed panel, ISO 9001:2015, compliant with Federal Decree-Law No. 45 of 2021 on PDPL | Often non‑accredited locally; lacks pediatric consent framework under Federal Law No. 2 of 2019 |
| Clinical Utility | Diagnostic, prognostic, and familial cascade testing in one assay | Diagnostic only; limited to known familial variant screens |
Physician Insight & Safety Protocols
“The UMOD gene test represents a clinical breakthrough for early identification of familial juvenile hyperuricemic nephropathy, a disorder frequently overlooked until advanced kidney damage has occurred. Correlation with a three‑generation family pedigree, serum uric acid levels, and renal imaging remains essential. A positive molecular finding should prompt cascade testing in all first‑degree relatives. Pre‑test genetic counselling is strongly advised to address implications for minors and reproductive decision‑making.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory & Medication Precautions
Medication Advisory
Do not discontinue or alter prescribed urate‑lowering therapy or any other medication without consulting your managing physician. Genetic test results complement but do not replace immediate clinical assessment or emergency intervention.
Exclusion Criteria & Red Flags
- Exclusion criteria: Allogeneic bone marrow transplantation within the past 12 months, blood transfusion within 2 weeks, or active haematologic malignancy (risk of somatic mosaicism). Not validated for prenatal diagnosis without prior genetic counselling. Samples should ideally be collected before initiating or adjusting urate‑lowering agents.
- Emergency red flags – seek immediate medical care if: Sudden severe flank pain, anuria (<50 mL urine/24 h), acute monoarticular arthritis with fever (suspected septic arthritis), or altered mental status with hyperuricemia (serum uric acid > 700 µmol/L).
- Pediatric requirement: For minors, written informed consent from a legal guardian is mandatory per the UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and Federal Law No. 2 of 2019 on health data protection.
Patient FAQ & Clinical Guidance
1. What exactly does the UMOD gene NGS test detect and what does a positive result mean for my family?
This test sequences the entire coding and regulatory regions of the UMOD gene to identify disease‑causing variants. A positive result confirms hereditary hyperuricemic nephropathy type 1, enabling early initiation of urate‑lowering therapy, regular renal monitoring, and cascade screening of at‑risk family members. All results are interpreted by a Consultant Medical Geneticist and accompanied by a detailed clinical report.
2. How is the sample collected and what preparation is needed?
A simple peripheral blood draw (2–5 mL in EDTA) is collected by our VIP Mobile Phlebotomy service between 8 AM and 11 PM, seven days a week. No fasting is required. Please inform our team of any recent blood transfusions, bone marrow transplants, or active malignancies that may affect DNA quality. The sample is transported under temperature‑controlled cold‑chain conditions to our ISO‑accredited laboratory in Dubai Healthcare City.
3. How reliable is this test compared to older methods and is it suitable for children?
Our NGS platform delivers >99.9% analytical sensitivity for single‑nucleotide variants and small indels, far surpassing Sanger sequencing. The test requires a minimal blood volume, making it safe for pediatric patients. All pediatric samples are processed under the guardianship consent framework specified in Federal Decree-Law No. 4 of 2016 on Medical Liability, and results are annotated with developmental and nephrological context.
4. Will my health insurance cover this genetic test?
DNA Labs UAE offers direct billing verification for most UAE‑based health insurance plans. Please forward your policy details via WhatsApp to +971 54 548 8731 for a pre‑authorisation check. Out‑of‑pocket cost is AED 2,800, inclusive of phlebotomy, genetic analysis, and the telephonic post‑test consultation.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Compliance Framework
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient genetic data. Clinical information systems are further governed by Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic testing and patient consent procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring secure handling, encryption, and access‑controlled storage of genomic data. Your results are confidential and shared only with you and your referring physician.
Clinical & Logistical Metadata
| Test Name | UMOD Gene Hyperuricemic Nephropathy, Familial Juvenile Type 1 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 21–28 calendar days |
| Sample Type / Matrix | Peripheral whole blood (EDTA), 2–5 mL; also accepted: extracted genomic DNA, FTA card spots |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina NovaSeq X Plus, paired‑end 150 bp, full gene ±20 kb flanking regions |
| ICD-10-CM Code | N11.0 (Non‑obstructive reflux‑associated chronic pyelonephritis; alternative: E79.0 for hyperuricemia without renal impairment) |
| LOINC Code | 94487-1 (UMOD gene mutation analysis in blood by NGS) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians